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Abstract
Background: Traumatic events like critical illness and intensive care are threats to life and bodily integrity and pose
a risk factor for posttraumatic stress disorder (PTSD). PTSD affects the quality of life and morbidity and may increase
health-care costs. Limited access to specialist care results in PTSD patients being treated in primary care settings.
Narrative exposure therapy (NET) is based on the principles of cognitive behavioral therapy and has shown positive
effects when delivered by health-care professionals other than psychologists.
The primary aims of the PICTURE trial (from “PTSD after ICU survival”) are to investigate the effectiveness and applicability
of NET adapted for primary care with case management in adults diagnosed with PTSD after intensive care.
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Methods/design: This is an investigator-initiated, multi-center, primary care-based, randomized controlled two-arm
parallel group, observer-blinded superiority trial conducted throughout Germany. In total, 340 adult patients with a total
score of at least 20 points on the posttraumatic diagnostic scale (PDS-5) 3 months after receiving intensive care treatment
will be equally randomized to two groups: NET combined with case management and improved treatment as usual
(iTAU). All primary care physicians (PCPs) involved will be instructed in the diagnosis and treatment of PTSD according to
current German guidelines. PCPs in the iTAU group will deliver usual care during three consultations. In the experimental
group, PCPs will additionally be trained to deliver an adapted version of NET (three sessions) supported by phone-based
case management by a medical assistant. At 6 and 12 months after randomization, structured blinded telephone
interviews will assess patient-reported outcomes.
The primary composite endpoint is the absolute change from baseline at month 6 in PTSD symptom severity measured
by the PDS-5 total score, which also incorporates the death of any study patients. Secondary outcomes cover the
domains depression, anxiety, disability, health-related quality-of-life, and cost-effectiveness. The principal analysis
is by intention to treat.
Discussion: If the superiority of the experimental intervention over usual care can be demonstrated, the combination
of brief NET and case management could be a treatment option to relieve PTSD-related symptoms and to improve
primary care after intensive care.
Trial registration: ClinicalTrials.gov, NCT03315390. Registered on 10 October 2017.
German Clinical Trials Register, DRKS00012589. Registered on 17 October 2017.
Keywords: Stress disorders (MeSH), Intensive care (MeSH), Non-pharmacological (NON-Mesh), Primary health care
(MeSH), Randomized controlled trial (MeSH)
Background
In Germany, more than two million people are treated in
intensive care units (ICUs) every year, more than 350,000
of whom undergo mechanical ventilation. These patients
may suffer long-term functional, psychological, or medical
sequelae [1–3], but there are only a limited number of
treatment options [4]. Posttraumatic stress disorder
(PTSD) is a common sequela (25–44%) of critical illness
and ICU treatment and has a substantial impact on
health-related quality of life and health-care-related costs
[5, 6]. Systematic screening and early interventions in pri-
mary care may improve outcomes [7, 8]. In Germany, a
guideline for treating patients with PTSD in primary care
recommends supportive symptomatic pharmacologic
therapy on a primary care level and referral to a specialist
for psychotherapy and other non-pharmacological inter-
ventions [9]. However, access to psychiatric and psycho-
therapeutic specialty services, e.g. trauma therapists, is
limited and waiting times are usually 5 months or longer
[10, 11]. During this time, a primary care physician (PCP)
is the main health-care professional attending to the pa-
tient. An effective psychological therapy for ICU-related
PTSD applicable to primary care is needed [12].
Trial rationale
Currently, the underlying mechanism of PTSD is assumed
to be a disturbance in the organization and processing of
memories of traumatic events, resulting in a separation of
sensory, cognitive, and affective representations from the
contextual and episodic memory system [13]. Patients
who suffer from traumatic stressful experiences cannot
clearly structure these events in chronological order and
are, thus, unable to place the anxiety and helplessness as-
sociated with these events appropriately in time and space.
Consequently, alarm responses can become activated by
even small, subtle prompts. The resulting change affects
the homeostasis of all physiological systems. The goal of
psychotherapeutic interventions for PTSD is to teach sur-
vivors which cues relate to traumatic experiences in the
past so that they no longer trigger an alarm response in
the present.
Narrative exposure therapy (NET) is a specific form of
psychotherapy for PTSD based on cognitive behavioral
therapy [13]. During this treatment, the patient develops
a narrative of traumatic events, which is meant to con-
solidate fragmented memories by setting these events
into their respective context of time, place, and situation.
NET typically consists of a session of psychoeducation,
followed by a session in which the patient creates a
graphical representation of their biography using a life-
line. Then, there are several sessions in which the pa-
tient recounts the stressful situations to recover
contextual details of the traumatic event. NET is effect-
ive even when limited to only three to four sessions and
also when delivered by health-care professionals other
than psychotherapists [14–16].
In this study, a psychological intervention combines a
brief version of NET adapted to primary care [13] with
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the principles of the chronic care model for special case
management (telephone monitoring by the medical as-
sistant or MA) [17]. The latter is one of the core compo-
nents of this model. It includes case management
focused on proactive patient symptom monitoring, clin-
ical decision support for the PCP, and training for PCPs
in evidence-based care.
A randomized controlled two-arm study of sepsis survi-
vors (SMOOTH trial) enrolled 291 adult patients between
February 2011 and December 2014 [18]. Patients were re-
cruited from nine ICUs across Germany after having sur-
vived sepsis and randomized to usual primary care or to a
12-month intervention, consisting of usual primary care
plus additional PCP and patient training, case manage-
ment provided by study nurses, and clinical decision sup-
port for PCPs by consulting physicians. Based on the
SMOOTH trial, which examined whether a primary care–
based intervention improved health-related quality of life
in adult sepsis survivors, we designed the PICTURE trial,
which aims to improve traumatic stress sequela for post
ICU-patients in a primary care setting [18].
Methods/design
Aims and objectives
The primary aims of the PICTURE trial (from “PTSD after
ICU survival”) are to investigate the effectiveness, safety,
and applicability of a brief NET-oriented primary care
intervention combined with systematic trauma monitor-
ing in ICU survivors compared to improved treatment as
usual (iTAU), and to assess the maintenance of a possible
treatment effect (defined as an improvement in
PTSD-related symptoms) and applicability assessed at 6
and 12 months after baseline.
Trial design and setting
PICTURE is a multi-center, two-arm parallel-group,
observer-blinded, randomized, active-controlled super-
iority trial. The trial will be conducted in primary care
practices across Germany. Trial management will be de-
livered by academic primary care institutes at university
hospitals around Munich, Berlin, Hamburg, Dresden,
Tübingen, and other areas. The primary care setting is
associated with long-lasting doctor–patient relationships
and coordination of health services, in accordance with
the definition of Starfield et al. [19].
Figure 1 is a flow chart for the study. This protocol fol-
lows the “Guidance of Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) 2013
statement” [20], and it includes the schedule of enrolment
and relevant assessments (Fig. 2) based on the SPIRIT fig-
ure template. A completed SPIRIT checklist is provided in
Additional file 1.
Pre-selection of eligible patients for trial recruitment and
informed consent procedures
Patients will be screened by ICU staff at the time of dis-
charge from the ICU if they meet the following criteria:
 male or female adults aged 18 to 85 years
 duration of mechanical ventilation ≥3 days
 Sequential Organ Failure Assessment (SOFA)
score ≥ 5 (i.e., the maximum SOFA score during the
ICU stay)
 life expectancy ≥9 months (as assessed by the
intensive care physician)
Screening at ICU discharge will use a short validated
paper-based questionnaire for cognition (Six-item Screener,
SIS) [21] and a short validated five-item version of the
Primary Care PTSD Screen (Primary Care PTSD Screen
for DSM-5, PC-PTSD-5) [22].
Screened patients with a PC-PTSD-5 total score ≥3
points and no signs of significant cognitive impairment,
i.e., with a SIS score ≥4 points, at ICU discharge will be
re-screened 10 weeks later by the study nurse (affiliated
at the corresponding trial site) via phone using the
PC-PTSD-5 questionnaire only.
If a PC-PTSD-5 score of ≥3 is measured during the
re-screening 10 weeks after ICU discharge, the patient
will asked to attend for a baseline assessment, including
confirmation of the PTSD diagnosis, at their PCP’s of-
fice. As a prerequisite for the baseline visit, the patient’s
PCP will be assessed for eligibility by the study nurses of
the corresponding trial site and asked for written in-
formed consent to participate in the trial, if all inclusion
criteria are met.
Target population and eligibility criteria
Inclusion and exclusion criteria for patients
For final inclusion, screened patients must meet all the
following inclusion criteria to be eligible for enrollment
into the trial at baseline:
 PTSD symptom level: 20-item Posttraumatic Stress
Diagnostic Scale for DSM-5, PDS-5 score ≥ 20 points
[23]
 able to follow study instructions and likely to attend
and complete all required visits and telephone surveys
 provide written informed consent
Patients are excluded from enrolment into the study if
any of the following exclusion criteria apply:
 insufficient understanding of the German language
 presence of a physical or psychiatric condition that
at their physician’s discretion may put the subject at
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Fig. 1 Study flow chart of the PICTURE trial: graphical depiction of study activities and components of intervention for both arms. BL baseline,
GCP good clinical practice, GP general practitioner, ICU intensive care unit, ITC investigator trial center, MA medical assistant, Pat. participant, PDS
Posttraumatic Stress Diagnostic Scale, PTSD posttraumatic stress disorder
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Fig. 2 Standard protocol items (SPIRIT) for the PICTURE trial: schedule of enrolment, intervention, and assessments with their pre-planned time
points T1 to T2. CSSRI Client Sociographic and Service Inventory, EQ-5D-5L Five-dimension Five-level EuroQol, ICU intensive care unit, iTAU improved
treatment as usual, NET Narrative exposure therapy, OASIS Overall Anxiety Severity and Impairment Scale, PAM Patient Activation Measure, PC-PTSD
Primary Care Posttraumatic Stress Disorder Screen, PCP primary care physician, PDS Posttraumatic Stress Diagnostic Scale, PHQ Patient health questionnaire,
SAE serious adverse event, SIS Six-item Screener, SOFA Sequential Organ Failure Assessment, WHODAS World Health Organization Assessment Schedule
Gensichen et al. Trials  (2018) 19:480 Page 5 of 14
risk, may confound the trial results, or may interfere
with the patient’s participation in this clinical trial
 known or persistent abuse of medication, drugs, or
alcohol
 major depression (PHQ-9 ≥ 23)
 acute suicidality
 life expectancy < 9 months (as assessed by the PCP)
 concomitant therapy: trauma-specific psychotherapy
at baseline
 intake of any neuroleptic, anticholinergic, or anti-
epileptic drugs up to 2 weeks prior to baseline
 severe PTSD symptoms (PDS-5 > 50)
Inclusion and exclusion criteria for PCPs
Inclusion criteria for participating PCPs are:
(1) The physician must have been registered for at
least 2 years in the German statutory health-care system
as a primary care physician.
(2a) The physician must have a qualification in basic
psychosomatic care (Psychosomatische Grundversor-
gung, Bundesärztekammer, 2001) [24] to ensure that
they can provide a basic level of mental health care and
to ensure patient safety.
(2b) Alternatively, the PCP must have been a family
doctor within the German statutory health-care system
for at least 5 years with evidence of adequate psychiatric
education, e.g., additional training (this is to ensure that
all participating PCPs have a minimum level of psychi-
atric knowledge).
(3) They have provided written informed consent.
PCPs with a specialization such that more than 80% of
the patients registered with their practice have a specific
mental condition are excluded from the trial to ensure
that enrolled practices are representative of German pri-
mary care.
Randomization and blinding
All fully screened patients who give written informed
consent for participation and who fulfill the eligibility
criteria will be randomized together with the attending
PCP. A full screening also includes confirmation of the
PTSD diagnosis by the treating PCP of the trial partici-
pant, together with the baseline assessment at T0.
Randomization is requested by the personnel of the cor-
responding study site no later than 2 weeks after the base-
line visit at T0. Concealed randomization to NET or iTAU
will be performed with a 1:1 allocation ratio. The
computer-generated randomization allocation sequence
considers stratification by study site defined by the corre-
sponding ICU. The sequence will be generated, and
randomization will be performed by an independent per-
son affiliated to the Institute for Medical Informatics,
Biometry and Epidemiology of the Ludwig Maximilian
University of Munich (LMU Munich) using the
web-based randomization tool Randoulette [25]. The
randomization list will not be accessible during the study.
After randomization, the relevant study site will have
immediate access to the allocation group via online ac-
cess to Randoulette and will inform the patient and the
PCP practice about the respective allocation status (NET
versus iTAU) via an official letter and ask the PCP prac-
tice to arrange the following appointments with the par-
ticipating patient. PCPs in the intervention group will
receive further information about the NET intervention
and individual training.
PCPs and patients know the treatment they deliver or
receive. However, this trial is designed to be observer--
blinded. The trained interview staff affiliated to the site of
the principal investigator (PI) at the Institute of General
Practice and Family Medicine at LMU Munich will collect
the patient-reported primary and secondary efficacy out-
comes blind to group assignment. Follow-up data will be
collected through structured telephone interviews at T1
and T2 without any access to additional patient data, case
report forms (CRFs), or the study database. The trial stat-
istician and the health economist will remain blinded to
randomization codes throughout the trial until the study
database has been finalized and locked.
Intervention period
Experimental condition
After randomization, PCPs in the intervention group will
receive training material (therapy manuals for PCPs and
MAs, intervention videos, and a paper booklet), as well
as face-to-face training by NET-qualified psychologists.
In most cases, the training for PCPs will be on a
one-to-one basis, though group training may also be ar-
ranged. Additionally, patients in the intervention group
will receive written information about PTSD and trial
procedures. Treatment in the intervention group con-
sists of three NET sessions delivered by the PCP and
case management delivered by the practice-based MA.
Furthermore, PCPs will receive training through written
materials with information regarding study procedures as
well as diagnostic examinations for and treatment of PTSD
according to the German S3 Guideline on PTSD [10].
Three NET sessions of approximately 45 min each will
be delivered by the PCP. The first session includes psy-
choeducation on PTSD and an overview of the patient’s
biography. In this session, the patient learns about the
symptoms and the theoretical background of PTSD as
well as the treatment procedure. In addition, they will
identify traumatic events in their biography by con-
structing a lifeline. In this procedure, the patient places
stickers of flowers and stones, symbols of important
positive and stressful events, in chronological order on a
line that they construct and draw together with the PCP
on a piece of paper. The line serves as a timeline,
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providing an overview of the patient’s biographical bur-
den and resources. At the end of the session, the recent
ICU event will be implemented in the lifeline.
In the second session, the patient will be exposed to the
traumatic events in a safe environment by giving a de-
tailed narration of their stressful experience during their
ICU stay. After the second session, a qualified psychologist
will provide telephone support to the PCP to review the
treatment so far, prepare the third session, and give guid-
ance and advice on the content and mode of delivery of
the therapy, if necessary. Narration on another stressful
key life event identified on the lifeline is recommended as
the topic for the third session. Alternatively, an additional
narration of the ICU event might be chosen, if no other
stressful key event can be identified, or if the ICU event is
still the major key event in the patient’s life.
The MAs receive written training material and personal
training on case management, which is carried out by
study nurses from the relevant regional trial centers. Case
management consists of seven short telephone calls
(approximately 15 min each), in which the MA asks about
the patient’s well-being, completes a PTSD-monitoring
checklist, and provides social acknowledgement of the ex-
periences the patient had during their critical illness. MAs
follow written instructions for structuring the dialog and
gathering information. Included in the instructions is a
color-coded rating system for the PTSD screening ques-
tionnaire results. Critical responses should prompt the
MA to inform the attending PCP immediately. Question-
naire responses are noted in the booklet. Two telephone
calls are made between the second and third NET ses-
sions, followed by an additional five telephone calls be-
tween the last NET session and T1 (Fig. 1).
Control condition
Patients allocated to the control group will receive iTAU
during at least three consultations with their PCP. Treat-
ment will be based on current German recommenda-
tions for the diagnosis and treatment of PTSD [10]
without further specifications from the study protocol.
PCPs will receive written training material and detailed
medical information about PTSD, based on the current
national guideline for PTSD and on the application of
good clinical practice in the conduct of clinical trials
[26]. Because of this explicit training, we consider this
treatment approach improved in comparison to treat-
ment as usual without any additional training.
Informed consent procedures
Prior to enrolment, straight after the eligibility of a
patient has been checked and confirmed during
re-screening 2 weeks before the baseline assessment at
T0, the eligibility of the relevant PCP will be assessed
during a telephone interview by the investigator at the
regional trial center. Once the PCP’s eligibility is con-
firmed and they show interest in participation in the
trial, both the patient and attending PCP will be pro-
vided with a full explanation of the trial in word and in
writing (patient information sheet and PCP information
sheet). These include detailed information about the ra-
tionale, design, conduct, potential benefits and risks, and
personal implications of the trial. After the information
has been provided to the patients and PCPs, they will be
given sufficient time (at least 24 h) to consider participa-
tion in the trial before they are asked to do so. It is im-
perative that written consent is obtained before any
trial-specific procedures commence. This ensures that
participants have a full understanding of the trial and
that the decision to participate is made voluntarily. PCPs
will have the opportunity to discuss questions and con-
cerns with the regional investigator on the phone. They
will then give their patients further information about
the trial and discuss open questions and concerns with
them, before asking for their patient’s informed consent.
All participants may withdraw their informed consent
from the trial at any time and without any negative con-
sequences for further treatment.
Study procedures and timing schedule
The baseline assessment (T0) takes place in a PCP prac-
tice 3 months after the patient’s discharge from ICU by
self-reported paper-based and interviewer questionnaires
during a consultation with the PCP. In the intervention
group, NET sessions start 4 weeks thereafter over a
period of 6 weeks. In the control group, patients receive
iTAU during three study-related consultations with their
PCP within 6 months up to T1. the primary efficacy out-
come will be assessed by self-reported paper-based ques-
tionnaires 6 months (T1) after the baseline visit (T0)
while secondary efficacy outcomes will be assessed
6 months (T1) and 12 months (T2) after the baseline
visit (T0) by observer-blinded telephone interviews. For
a detailed description of study activities and the compo-
nents of the intervention, see Fig. 1. The end of the clin-
ical trial is defined by the last individual trial-specific
examination during the last visit of the last patient who
is participating in the trial.
Participation discontinuation
If a patient withdraws their written informed consent or
there is serious adverse event (SAE), the assigned study
intervention will be discontinued for them. SAEs are de-
fined as a patient’s death, life-threatening event, clinically
relevant severe deterioration of depression or PTSD
symptoms, acute suicidality, or adverse events that
would constitute an unacceptable risk for the patient.
The PCP will decide which incidents have to be followed
up as SAEs and will report them accordingly to the PI.
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All SAEs will be evaluated by the PI. Additionally, a sec-
ond evaluation of seriousness, causality, and expected-
ness will be performed by the Data and Safety
Monitoring Board (DSMB) at the PI’s discretion to en-
sure safety evaluations follow the four-eye principle.
Whenever a patient is withdrawn from the trial, the
reasons for the withdrawal or treatment discontinuation
together with the corresponding dates should be re-
corded in detail in the patient’s medical records and the
CRF. If a patient completely drops out from the study, a
final examination should be conducted (e.g., by phone).
In particular, every effort should be taken to assess the
primary outcome. If a patient does not return for a
scheduled (telephone) visit, every effort should be made
to contact them to regain them for further visits accord-
ing to the protocol.
For a drop-out or withdrawal of a PCP or for a SAE, im-
mediate support will be available through the Depart-
ments of Psychiatry affiliated to the relevant regional trial
center to ensure there is adequate care for patients with
PTSD. The emergency back-up centers (Prof. Falkai, De-
partment of Psychiatry and Psychotherapy, LMU Munich;
Prof. Förstl, Department of Psychiatry and Psychotherapy,
Technical University of Munich; Prof. Heinz, Department
of Psychiatry and Psychotherapy, Universitätsmedizin
Berlin, Campus Charité Mitte; Prof. Gallinat, Department
of Psychiatry and Psychotherapy, University Medical Cen-
ter Hamburg-Eppendorf; Prof. Bauer, Department of
Psychiatry and Psychotherapy, University Hospital Carl
Gustav Carus, Technische Universität Dresden; Prof.
Elbert, Clinical Psychology, University of Konstanz) will
be instructed accordingly. Affected trial participants will
be part of the full analysis set according to the intention-
to-treat (ITT) principle.
Patient-reported outcomes
Primary efficacy outcome and endpoint
To evaluate the PTSD symptom severity of trial partici-
pants, the German version of the self-administered
PDS-5 questionnaire will be applied. Each of the 20
items refers to PTSD-related symptoms experienced in
the past month and is answered on a five-point Likert
scale (from 0 not at all to 4 more than five times per
week/severe) [23, 27].
The primary efficacy outcome is the PDS-5 total sever-
ity score ranging from 0 to 80 points. The pre-specified
primary efficacy endpoint is the absolute change from
baseline to the 6-month follow-up telephone assessment.
Secondary efficacy outcomes
Patient questionnaires to derive secondary efficacy out-
comes were chosen based on the conceptual framework
of core outcome sets [28, 29].
As depression and anxiety are known common comor-
bidities in patients with PTSD, trial participants are
instructed to complete the primary care validated Patient
Health Questionnaire 9 (PHQ-9), where each of the nine
items is scored from 0 (not at all) to 3 (nearly every day),
resulting in a total score of from 0 to 27 points (large
scores indicate severe impairment) [30]. Anxiety will be
measured by the brief Overall Anxiety Severity and Im-
pairment Scale (OASIS) questionnaire, which contains five
response options for each of the five items, coded from 0
to 4. The total score ranges from 0 (no anxiety) to 20
points, with a high score indicating severe impairment
[31]. Disability will be assessed by the 12-item version of
the World Health Organization Disability Assessment
Schedule 2.0 (WHODAS 2.0), with a total score ranging
from 0 to 100 and higher scores indicating higher levels of
disability [32]. Patient activation will be measured by the
13-item Patient Activation Measure (PAM) [33], where
each item scores from 1 to 4 (1 strongly disagree, 2 dis-
agree, 3 agree, and 4 strongly agree; for the fifth item only,
5 is for not applicable). The evaluation for the latter is
made by adding the raw values, which have a range of 13–
52, and normalizing them to a scale of 0–100. We will use
the version of the EuroQol questionnaire with five dimen-
sions and five levels (EQ-5D-5L), which consists of the EQ
descriptive system and the visual analogue scale (EQ-VAS)
to measure health-related quality of life. The EQ-VAS is a
thermometer-like rating scale ranging from 0 (worst im-
aginable health state) to 100 (best imaginable health state
today) [34, 35]. Concomitant drug and non-drug therap-
ies, and health service use will be assessed by means of a
modified (shortened) German version of the Client Socio-
graphic and Service receipt Inventory (CSSRI) [36].
For all these scores derived from the questionnaires
mentioned above, the treatment effect will be assessed by
means of the absolute change from baseline at months 6
and 12 for secondary efficacy outcomes. The detailed
schedule of enrolment, interventions, and assessments
with their pre-planned time points is shown in Fig. 2.
Accompanying studies
Health economic evaluation
The objective of the health economic evaluation along-
side the main trial is to assess the cost-effectiveness of
the NET-oriented intervention in comparison to iTAU
from a societal perspective [37]. We will consider
health-care costs as well as productivity losses to de-
scribe the monetary consequences of the intervention
and calculate quality-adjusted life years (QALYs) as a
measure of the effects. These results will inform decision
makers in the health-care sector of the economic aspects
of the NET intervention and support them in deciding
whether the intervention should be implemented in the
German health-care system.
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Genetic evaluation
As the first side project of the trial, we also plan to in-
vestigate the genetic distinctiveness of patients after
intensive care medicine. We will consider differences in
the genetic characteristics of ICU patients with PTSD
compared to those of ICU patients without PTSD (not
participants of the PICTURE trial). The genetic evalu-
ation will be carried out in collaboration with the Insti-
tute of Psychiatric Phenomics and Genomics, University
Hospital Munich. This project has a separate trial proto-
col, which has the approval of the ethics committee, and
it requires separate written informed consent.
Process evaluation
A second side project will explore the experience of the
major actors (PCPs and MAs) and patients recruited at
ICUs in Berlin, Hamburg, and Dresden with the experi-
mental intervention in the NET group. This project aims
to analyze the applicability of the experimental interven-
tion. That is, it will investigate the beneficial and obstruct-
ive factors in the effectiveness, acceptance, and feasibility
of the intervention, based on the theoretical framework of
acceptability [38]. Qualitative interviews will be carried
out with PCPs, MAs, and patients after assessing the pri-
mary endpoint at T1 for the last patient randomized.
Statistical planning and analyses
Power considerations and sample size calculation
The current literature does not provide a minimal clinic-
ally important difference for the primary outcome (PDS-5
total score for DSM-5), on which we could base the
sample size calculation [39]. Therefore, we will use a cali-
bration argument to provide a rather pragmatic minimal
clinically important difference for this trial. Previous NET
studies defined a decline of about 25% in the baseline
score as a clinically relevant change [16]. Based on the
range of the PDS-5 score from 0 to 80 points, we define
40 as the mean baseline score. Thus, a 25% change from
baseline gives 10 points as the mean absolute decrease. To
be more conservative (also assuming a slight effect of 4
points within the control group), we consider a difference
in absolute change of 6 points between both groups as
clinically relevant for these post-ICU patients. Using a
standard deviation of 17, this translates into a Cohen’s d
(standardized effect size) of 0.36. This effect is assumed to
be conservative compared to the reported effects for NET
[13, 40]. It can be translated into a probability of 0.6 that
the observed decrease in the experimental group is larger
than that in the control group (assuming a standard nor-
mal distribution). The probability of 0.6 is the target par-
ameter needed to perform a sample size calculation with
the Wilcoxon–Mann–Whitney rank-sum test. A sample
size of 131 patients in each group, i.e. 262 patients in total,
will have 80% power to detect a decrease of PDS-5 in the
intervention group as described above compared to the
control group using a Wilcoxon–Mann–Whitney rank-
sum test with a 0.05 two-sided significance level (software
used: nQuery Advisor 7.0). To incorporate the death of
patients (resulting in the efficacy outcome being truncated
due to death), we apply a non-parametric worst rank score
analysis ([41, 42], for details see below) and decided to
randomize an additional 78 (= 2 × 39) patients [an in-
crease of about 30% (= 39 / 131) derived from a simula-
tion study]. Thus, the sample size to be allocated to the
trial is 2 × (131 + 39) = 340 patients in total.
It is anticipated that 3000 patients can be pre-screened,
of which 1000 (33%) are expected to show posttraumatic
stress [5]. The rate of non-participation is expected to be
about 35%, which is a conservative assumption compared
to our previous study (20% non-participants in [18]).
Therefore, 650 (65%) are expected to be willing to partici-
pate (patients and their PCPs). Of these, 550 patients
(about 85%) could be screened by their treating PCP
3 months post-ICU discharge (assuming a mortality rate
after 6 months of about 15% as in [18]), 400 (about 70%)
could meet the inclusion criteria, and 340 (85%) patients
(and their PCPs) could consent to participate in the study
at the baseline visit. We assume a 30% drop-out rate from
baseline over the 6 months before the primary endpoint is
assessed. There is no pre-planned interim efficacy analysis
and no sample size recalculation.
Statistical analyses for primary and secondary endpoints
The primary efficacy endpoint is the absolute change in
the PDS total severity score from baseline at month 6:
ΔPDS = PDS(T1) – PDS(T0).
By default, the mode of administration is a self-administered
paper-based version. For patients who do not complete
and send back the paper-based patient questionnaire
(non-responding survivors), the PDS-5 total score will
be assessed during the telephone surveys scheduled
6 months (T1) and 12 months (T2) after randomization.
It is assumed that death is the most likely cause of miss-
ingness. Therefore, a composite endpoint approach will be
applied, combining information about the change in PDS
total score and mortality into a single variable [41].
The null hypothesis, GNET(x) =GiTAU(x) and KNET(t) =
KiTAU(t) (0 < t ≤ T, date of death), implies that treatment
groups NET and iTAU will not differ with respect to the
distributions of the observed outcome measure ΔPDS.
Here, G(x) is the cumulative probability distribution of
the observed change in PDS severity scores at T1 in
groups NET or iTAU, and the distribution K(t) of the
date of death is the cumulative distribution of inform-
ative event times for the compared groups.
The null hypothesis will be tested by a non-parametric
approach using a modified version of the Wilcoxon–
Mann–Whitney U test, which basically allocates the tied
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worst ranks to all missing values (the worst rank score
analysis was proposed by Lachin [42]). The null hypoth-
esis can be rejected if the two-sided p value related to
the test statistic for the treatment effect is equal to or
smaller than the significance level α = 0.05. This test
strategy is tailored to a particular alternative hypothesis,
i.e., (i) NET will either be superior to iTAU in terms of
ΔPDS, but with no impact on survival, (ii) NET will be
superior to iTAU in terms of survival, but with no im-
pact on ΔPDS, or (iii) NET will be superior to iTAU for
both ΔPDS and survival.
If the PDS total severity scores are not informative for
future death events, the worst rank replacement will
simply lead to a power loss and no inflation in the type I
error rate. Should the PDS total severity scores be in-
formative for future death events, the worst rank re-
placement will result in an unbiased test of a particular
alternative [42].
The principal analysis will be performed according to
the ITT principle, and not adjusted for screening or
baseline covariates or site. The significance level is set to
alpha = 5% (two-sided).
Missing data prior to the follow-up measurement will
occur because of an informative disease-related event
(e.g., death or morbidity) or for other reasons (e.g.,
non-responders at follow-up measurements at T1 and
T2, loss to follow-up, or consent withdrawn). To address
the impact of several missingness mechanisms (missing
at random or missing not at random), sensitivity ana-
lyses will be performed: mixed effect models assuming
missing at random using the whole observed longitu-
dinal PDS profile of the surviving patient; multiple im-
putations techniques; or even complete case analyses
using the analysis of covariance (absolute change score
as the response variable and treatment group as the co-
variate, adjusting for the baseline score value) for
responding survivors until T1.
Moreover, sensitivity analyses will be performed in the
per-protocol population using linear mixed effects
models to explore the role of covariates (e.g., patient age
and gender).
The full statistical analysis plan will be finalized and
revised in a blinded manner ahead of the database lock
after the last patient’s last 12-month telephone call.
Definition of analysis data sets
Each trial participant’s allocation to the different analysis
populations (full analysis data set according to the ITT
principle, per-protocol analysis data set, and safety ana-
lysis data set) will be defined and explained in the statis-
tical analysis plan, which will be finalized before the
analysis. During the data review, deviations from the
protocol will be assessed as minor or major. Major devi-
ations from the protocol will lead to the exclusion of a
participant from the per-protocol analysis data set. The
full analysis data set according to the ITT principle will
consider all randomized patients with at least one
study-related visit at a physician’s office during the inter-
vention period (for the NET group, at least one NET ses-
sion and for the iTAU group, at least one face-to-face
consultation). Furthermore, patients who die before the
evaluation of efficacy outcomes (truncation due to
death) are part of the principal analysis incorporating
the timing of death of the trial participant.
Safety assessment and reporting of adverse events
Overall, a low frequency of SAEs can be expected due to
the narrative exposure itself. SAEs are events that (1) result
in death, (2) are life-threatening, (3) require hospitalization
or cause prolongation of existing hospitalization, (4) result
in persistent or significant disability or incapability, (5) are a
congenital anomaly or birth defect, or (6) require interven-
tion to prevent permanent impairment or damage. SAEs
will be regularly monitored and investigated from the start
of the intervention at Session 1 in the NET group and from
the first of the three PCP consultations in the iTAU-group
until the end of the trial at T2. The PCP will decide which
events have to be followed up as SAEs and will report them
accordingly to the PI.
The PCP is the first point of contact during the inter-
vention period, since the telephone interviews are at T1
and T2. If a patient cannot be reached via telephone at T1
and T2, the RTC will contact the respective PCP for fur-
ther information on the patient’s possible SAE status. For
the whole trial duration from T0 up to T2, the PCP is
instructed to report all SAEs, or the relocation or death of
the patient proactively. Since in Germany the PCP is the
first point of contact to receive updates from hospitals,
specialists, or other medical services involved in the pa-
tient’s care, this should enable us to monitor patient safety
continuously. In addition, psychiatric back-up clinics are
available at each site for emergency cases. All SAEs will be
reported to the PI and the DSMB.
Since there is a great heterogeneity in adverse events in
primary care, it is sometimes not possible to differentiate
between adverse events and pure signs of discomfort in
patients [43]. Therefore, we decided not to assess any ad-
verse events. All documented SAEs will be listed by study
site and patient and displayed in summary tables. The in-
cidence of SAEs and their relationship to the assigned
intervention will be descriptively analyzed [44, 45].
Data management
The Institute of General Practice and Family Medicine,
University Hospital, LMU Munich, as the coordinating
study center, is responsible for data management, which
encompasses all tasks concerning processing and
utilization of study data, with the aim of guaranteeing
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high-quality data and providing a valid study database
for statistical analyses. All data management activities
will be done according to the current standard operating
procedures of the investigational trial center (ITC).
Data collection and transmission
All data collected during the trial will be documented
using electronic case report forms (eCRFs). The source
data will be stored regionally in the patients’ files. Clin-
ical and patient-reported outcome data will be collected
by the ITC in Munich at the site of the PI via
self-administered questionnaires and via phone inter-
views at T1 and T2. ITC staff are blinded to the assigned
treatment given to the interviewed patient.
Data handling
Data collection will be managed using a secure,
web-based system (OpenClinica© Community Edition,
Version 3.12). Data input requires an internet connec-
tion and a browser. Authorization and the electronic sig-
nature of users is granted via a login and password. To
ensure the security of the data entered, web access is
encrypted via SSL certificates. All data collected
throughout the study period will be stored in a secure
server at the Leibniz Supercomputing Centre of the Bav-
arian Academy of Sciences and Humanities (Leibniz-Re-
chenzentrum, LRZ). A secure file folder will be
constructed before initiation of the trial. Access is lim-
ited to the PI and the data manager. Study participants
will be identifiable through their study-specific screening
number. Data routinely collected from patients, includ-
ing questionnaire data, will be stored at the trial site up
to T1 and at the coordinating trial center in Munich at
T1 and T2, using eCRFs.
Any changes made during data collection will be docu-
mented using audit trails in OpenClinica. Data integrity is
enforced by referential data rules, valid values, range
checks, and consistency checks against data already stored
in the database. Plausibility checks will be applied during
data entry and before the data are transferred to the data-
base. To ensure valid comparable data, data cleaning is
carried out according to a data validation plan. After the
database is locked, all study data will be exported from
OpenClinica© for statistical analyses using SAS (Institute
Inc., Cary, NC, USA) or the software package R, version
3.5.0 or higher (www.R-project.org).
Monitoring
An independent clinical monitor will check for accuracy,
completeness, consistency, and reliability of the eCRFs
by comparing documented data with source data. The
monitor will check that data are collected, stored, and
managed appropriately at all trial sites. Additionally, the
monitor will check SAE documentation and status as
well as documentation and follow-up of protocol devia-
tions. Monitoring visits will be carried out regularly ac-
cording to the standard operating procedures at each
trial site independently, to ensure the trial procedure is
executed according to good clinical practice [26].
Data safety and monitoring board
An independent DSMB has been established to monitor
the course of the study, recruitment, patient safety, the
integrity of the trial, and if necessary to give a recom-
mendation to the coordinating investigator and sponsor
for discontinuation, modification, or continuation of the
study. Furthermore, the DSMB will periodically review
the safety-relevant events reported to this board. The
members of the DSMB are Dr. Jochem König (Mainz),
Dr. Andreas Linde (Königsfelden), Prof. Wolfgang Milt-
ner (Jena), and Prof. Frank Schneider (Aachen).
Discussion
The aim of the PICTURE trial is to evaluate the effect of
a multicomponent primary-care-based intervention for
ICU survivors suffering from posttraumatic stress. Since
PTSD after critical illness is still an underestimated
problem and PCPs are the first point of contact for pro-
viding health care to these patients, it might be benefi-
cial to investigate this disease in ICU survivors and for
the PCP to acquire new non-pharmacological treatment
options to help these patients quickly during the typic-
ally long waiting periods for specialist support and ther-
apy. Therefore, it is important to assess the effects of
NET adapted to the primary care setting. The patient
and the attending PCP are the information units within
this trial. A single PCP will treat only one ICU patient
(i.e. the first to be randomized). Therefore, all conclu-
sions from the PICTURE trial will be limited to the pair
of patient and PCP.
Assuming a representative population of PTSD pa-
tients and a representative population of ICU patients,
the effect may be interpretable in a generalizable way,
and it may reflect a general statement about the efficacy
of a German, randomly chosen PCP who meets a ran-
domly chosen patient. This generalizability might be re-
duced by specific selection processes (e.g., PCPs eager to
join the trial, the long-term effect of the training,
whether the PCP is eager to learn more about NET,
whether there is a declining efficacy curve for PCPs, or
how MAs deliver the phone support, which is the sec-
ond component of the experimental intervention). These
also need to be elucidated in specific sensitivity and
process analyses.
Furthermore, this is a complex intervention and claims
cannot be linked or partitioned into specific compo-
nents. However, the involvement of physicians in pri-
mary care also poses certain challenges, as doctors
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usually have no experience in conducting clinical trials,
which might make it difficult to implement certain study
procedures. For this reason, before the beginning of the
intervention phase, the participating physicians will be
trained not only in study-specific procedures but also in
the basics of good clinical practice as prescribed by the
International Council for Harmonisation of Technical
Requirements for Pharmaceuticals for Human Use.
PICTURE may have further limitations. A selection
bias of participating PCPs and patients may limit the
generalizability of the results. The control group delivers
iTAU, which might not be representative for usual care
in general but might be more thorough and conscien-
tious. Even though the applied NET is adapted to the
primary care setting, there may still be barriers to imple-
mentation in daily clinical practice, e.g. due to limited
time resources in PCP practices. If two or more partici-
pating PCPs from the same practice have patients
assigned to different treatment groups, there may be
contamination between the intervention and control
participants. If a PCP has more than one relevant pa-
tient, only the first patient randomized will be included
in the full analysis data set. We expect this scenario to
be rather unlikely, and it would lead to individual
randomization instead of a cluster randomized design.
A major risk in the execution of the study could be in-
sufficient recruitment due to the gradual integration of
patients. To reduce this risk, we intensified the screening
and recruitment procedure carried out in the SMOOTH
trial, which was performed in and around Jena and
Berlin, by increasing the number of recruitment areas to
Berlin, Dresden, Hamburg, Tübingen, and Munich. In
each catchment area, we employ study nurses to moni-
tor and support screening and recruitment. The risk of
adoption (learning) of the intervention by PCPs may
lead to heterogeneity in intervention delivery. We may
be able to reduce heterogeneity in the intervention by
limiting the number of patients for each PCP (one pa-
tient per PCP).
Trial status
At the time of manuscript submission, the study design
has been evaluated by an independent international re-
viewer and has been approved by the ethics committee
of LMU Munich. The first patient was pre-screened at
an ICU at the end of October 2017 with the opening of
the trial site of the PI (start of patient recruitment) in
Munich. Until 26 April 2018, no study participants have
been randomized. We expect enrolment of the first pa-
tient in summer 2018.
Protocol version
Version 3.0, 14 March 2018.
Additional file
Additional file 1: SPIRIT 2013 Checklist. (DOC 120 kb)
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